Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.
Stocchi
F
F
IRRCS Neuromed, Pozzilli (IS), Italy.
Vacca
L
L
Grassini
P
P
Battaglia
G
G
Onofrj
M
M
Valente
M
M
Ruggieri
S
S
D002396:Catechols / Q000494:pharmacology* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007980:Levodopa / Q000097:blood / Q000493:pharmacokinetics*; D009570:Nitriles; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D013997:Time Factors
D002396:Catechols; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D009570:Nitriles; D007980:Levodopa; C071192:entacapone